Evidence map›Paper›PMID 27251610›Full record

ArticleAnnals of clinical microbiology and antimicrobials2016

Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.

Kwamena William Coleman Sagoe, Kwabena Obeng Duedu, Francesca Ziga, Afrakoma Adjoa Agyei, Theophilus Korku Adiku, Margaret Lartey, Julius Abraham Addo Mingle, Max Arens

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kwamena William Coleman SagoeDepartment of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana. ksagoe@ug.edu.gh.
Kwabena Obeng DueduDepartment of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.
Francesca ZigaPharmacy Department, Korle-Bu Teaching Hospital, Accra, Ghana.
Afrakoma Adjoa AgyeiDepartment of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.
Theophilus Korku AdikuDepartment of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.
Margaret LarteyDepartment of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.
Julius Abraham Addo MingleDepartment of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.
Max ArensRetrovirus Laboratory, Department of Pediatrics, Washington University Medical School, St. Louis, MO, USA.
University of Ghana · GHKorle Bu Teaching Hospital · GHWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCo-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection.

methodsPlasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed.

resultsThe presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (ρ = -0.441, p = 0.040), while the pre-ART HIV-1 VL (ρ = 0.844, p = <0.001) and sex (U = 19.0, p = 0.020) also determined HIV-1 viral load outcomes after 28 days of ART. Even though the geometric sensitivity score of HIV-1 strains were influenced by the HIV-1 subtypes (U = 56.00; p = 0.036), it was not a confounder for ART outcomes.

conclusionsThere may be the need to consider the confounder effects of sex, pre-ART CD4(+), and pre-ART HIV-1 viral load in the discourse on HIV and HBV co-infection.

Indexed as

AdultAfrica, WesternAntiretroviral Therapy, Highly ActiveAntiviral AgentsCD4 Lymphocyte CountCoinfectionFemaleGenotypeHepatitis BHepatitis B virusHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedAntiviral AgentsRNA, ViralAntiretroviral therapyCo-infectionDrug resistanceHepatitis B virusHuman immunodeficiency virusShort-term therapy

Identifiers

PMID27251610
PMCPMC4890471
OpenAlexW2414347898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.